Browse the evidence

GLP-1 receptor agonist type drugs can help patients achieve considerable weight loss.

Practitioners can consider GLP-1 RAs as a treatment option for weight loss in obese patients.

Nutritional deficiencies, particularly in vitamins and minerals, necessitate dietary counseling and supplementation for post-weight-loss patients.

Dietary counseling should be integrated into post-weight-loss care.

The use of weight reduction medications as an adjunct therapy alongside dietary, exercise, and behavioral interventions is clearly described in current and future guidelines of the German Obesity Society.

Practitioners should consider weight reduction medications as part of a comprehensive treatment plan.

Liraglutide reduced total body mass and lowered absolute and percent android fat over 18 days.

Liraglutide may be effective for weight loss in individuals with type 2 diabetes.

Bariatric surgery is the most durable and effective treatment for severe obesity.

Clinicians should consider bariatric surgery for patients with severe obesity.

The Atrial Fibrillation Better Care pathway emphasizes lifestyle modifications and weight loss strategies for managing AF in obesity.

Implementing lifestyle changes is essential for managing AF in obese patients.

Tirzepatide significantly reduced body weight, BMI, and waist circumference compared with placebo.

Tirzepatide may be an effective treatment for reducing body weight and improving BMI in Chinese adults.

Ecnoglutide produced mean weight loss of –9.9% (1.2 mg), –13.3% (1.8 mg), and –15.4% (2.4 mg) from baseline at 48 weeks, compared with –0.3% with placebo.

Ecnoglutide is effective for weight loss in Asian populations.

78%–93% of participants achieved ≥5% weight reduction with ecnoglutide.

A significant proportion of users can expect meaningful weight loss.

Weight-reduced patients lost 7.2% total body weight (TBW) versus 10.3% in non-weight-reduced patients (p < 0.001).

Practitioners should consider weight-reduction status when evaluating weight loss outcomes with tirzepatide.

Patients switching from semaglutide due to plateau lost 8.1% TBW versus 2.9% for non-responders (p < 0.001).

Switching from semaglutide may yield different weight loss results based on prior response.

Endoluminal interventions should be combined with a moderately intensive diet and lifestyle program lasting at least 12 months for optimal results.

Practitioners should integrate dietary and lifestyle counseling with endoluminal therapies for better outcomes.

Consuming protein three times a day results in an increase in lean mass of 1.15 kg after 8 weeks of resistance training.

Practitioners can recommend three protein meals per day to support muscle gain.

Consuming protein five times a day results in an increase in lean mass of 0.63 kg after 8 weeks of resistance training.

Practitioners can recommend five protein meals per day to support muscle gain.

Daily protein intake in patients' usual diets was below the recommended levels.

It is important to assess and address protein intake in patients with chronic lung disease.

A 40% energy surplus over 6 weeks significantly increased body protein mass by 3.7% (0.44 kg; 95% CI, 0.21-0.67 kg; P = 0.003).

Increasing energy intake significantly promotes body protein mass gain in healthy young men.

Protein supplementation may provide benefits for individuals with previous training experience, those not meeting daily protein requirements, or displaying frailty symptoms.

Protein supplementation may be beneficial for certain subgroups of older adults.

The SALUD program aims to improve food literacy in people with type 2 diabetes mellitus (T2DM).

Practitioners can utilize the SALUD program to enhance food literacy among T2DM patients.

The SALUD program includes 12 weekly web-based group sessions supervised by a certified lifestyle coach.

Health professionals can implement structured group sessions to support T2DM patients.

The intervention group had a significantly lower visceral fat area (Z = -6.79, P < 0.001) compared to the control group.

Implementing goal attainment theory-based interventions can effectively reduce visceral fat in physically inactive emerging adults.

The intervention group showed higher levels of physical activity, including vigorous (Z = 60.51, P < 0.001) and moderate activity (Z = 104.90, P < 0.001).

Encouraging goal-oriented physical activity interventions can significantly enhance activity levels in inactive young adults.

The HbA1c of the plate group significantly decreased at the endpoint (7.74±0.45% vs. 6.70±0.46%, P<0.001).

The plate model may effectively lower HbA1c levels in newly diagnosed type 2 diabetes patients.

The optimal SPAN combination of 8.0-9.4 h/day sleep, 42-104 min/day MVPA, and a DQS of 32.5-50.0 was associated with a 57% lower risk of major adverse cardiovascular events (MACE) (HR: 0.43; 95% CI: 0.30, 0.62).

Practitioners should encourage optimal sleep, physical activity, and nutrition combinations to reduce cardiovascular event risk.

A minimum combined variation of an additional 11 min/day of sleep, 4.5 min/day MVPA, and 3 DQS points was associated with 10% lower MACE risk (HR: 0.90; 0.88, 0.94).

Small improvements in sleep, activity, and diet can significantly reduce cardiovascular event risk.